Navigation Links
Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
Date:5/8/2013

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release
'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
2. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
3. Vermillion Reports Fourth Quarter and Full Year 2012 Results
4. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
5. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
6. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
7. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
8. Vermillion Reports Third Quarter 2012 Results
9. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
10. Vermillion to Present at the 2012 Gateway Conference on September 6
11. Vermillion Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
(Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:9/17/2014)... (PRWEB) September 17, 2014 With ... have special functions of adjusting human body physiology, ... won great popularity with a variety of specific ... food in China reached RMB187.4 billion, up 12.0% ... during 2006-2013. , China's health product industry is ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
(Date:9/17/2014)... 17, 2014 Researchers say patients with ... least likely to have good outcomes with chemotherapy treatment. ... findings. Click here to read it now. ... Levine Cancer Institute in North Carolina analyzed 30 published ... the 137 patients with sarcomatoid mesothelioma had ...
(Date:9/17/2014)... 17, 2014 There’s something changing ... girls of all ages an all-natural option for ... by women, for women, announces the launch of ... to relieve the symptoms commonly associated with ... , As a lifelong health enthusiast and ...
(Date:9/17/2014)... September 17, 2014 Request A Test ... testing, is offering 10% off drug testing through ... all drug tests, including those ordered by employers for workplace ... advantage of this discount by using promo code DRUG10 when ... in positives on workplace drug testing, especially for marijuana or ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Doctors Find Lower Treatment Response in Those with Rare Type of Mesothelioma, According to Surviving Mesothelioma 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
... Jeff Klein Renowned for IVF Success, NEWBURGH, ... clinical affiliate of The Mount Sinai Hospital, is ... region with the addition of,Reproductive Endocrinologist Jeffrey Klein, ... medical director of the Westchester division of,Reproductive Medicine ...
... PITTSBURGH and PLYMOUTH MEETING, Pa., March 12 ... Maintenance,Management Systems (CMMS) for the healthcare industry and ... approaches to improving,patient care, announce the availability of ... and recall alert applications., This new ...
... air purifier,delivers cleaner and healthier air. It effectively ... pollutants that affect us every day at work ... value through the unbeatable,combination of consumer benefits., ... and Ozone Cause Severe Health Problems, Millions ...
... University of Warwick has uncovered exactly how the bacterium ... The same research could also open up MRSA to ... designer antibiotics to use against a range of other ... fatal pneumonia infections a year in children. In the ...
... . , Quebec City, March 12, 2008A research ... identified genetic markers that allow the selection of eggs ... after in vitro fertilization (IVF). This finding could both ... diminish the risk of multiple pregnancies. The details of ...
... 12, 2008 AstraZeneca (NYSE: AZN) announced today that ... III studies for vandetanib, the companys investigational, once-daily oral ... lung cancer (NSCLC). The two studies ZODIAC (ZACTIMA ... and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) ...
Cached Medicine News:Health News:SLCH Brings Infertility Specialist to Region 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 3Health News:LightAir Cleans the Air From the Smallest and Most Dangerous Particles Without Generating Ozone 2Health News:Research could put penicillin back in battle against antibiotic resistant bugs that kill millions 2Health News:Researchers develop a method to select eggs with the best chance of leading to successful pregnancy 2Health News:Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib 2
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Medicine Products: